ASX ANNOUNCEMENT

October 18th, 2010

Presentation

Genetic Technologies Limited (ASX: GTG; NASDAQ: GENE) is pleased to release a copy of the presentation that will be made by Dr. Paul MacLeman, Chief Executive Officer, at the 2010 Australian Life Science Summit in Melbourne tomorrow.

FOR FURTHER INFORMATION PLEASE CONTACT

Thomas G. Howitt
Company Secretary

Genetic Technologies Limited
Phone: +61 3 8412 7000

GENETIC TECHNOLOGIES LIMITED

Highlights

- $10m revenue 2009/10 with tapering burn rate
- Cancer diagnostics and genetic testing focus
- Revenue generating IP estate
- High growth prospects through launch first in class sporadic breast cancer risk test globally

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445

Snapshot

- 20yo laboratory services business with mature but stable underlying businesses
- Substantial near term growth opportunities in cancer diagnostics, with recent successes
- Existing & increasing revenues from IP out-licensing
  - US IP assertion suit: ~A$3m gross last quarter
- Building new global business via acquisition, development & deployment of high value diagnostics
- Based in Melbourne & US
  - 60 highly qualified staff
  - Globally accredited facilities

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445

Cancer Management Portfolio Strategy

- **Unique portfolio approach: global deployment in-house tests**
- **Assembling best in class cancer management tools for PacRim deployment: further products in negotiation**
- **Seeking to develop &/or acquire products with global protection, application & scope**

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445

BREVAGen™

- Proprietary breast cancer test
  - Clinical decision support for **non-familial** breast cancer screening & preventive therapy
- Test combines population risk factors (Gail Score) with genetic risk factors (7 SNP biomarkers) to give integrated, individual breast cancer risk assessment
- First fully validated test of its kind
- BREVAGen™ informs clinicians & patients about personal, non-familial risk of breast cancer for women, allowing better patient monitoring & potentially preventive therapy

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445

BREVAGen™ – first validated test for non-familial breast cancer risk

BREVAGen™

Gail Score

Invasive breast cancer

Cancer 20%

Biopsy

Abnormal 65%

BREVAGen™

Normal 15%

Normal Tissue

Avoid unnecessary Rx

Annual mammograms

SERM Rx eg Tamoxifen

- 1.6m breast biopsy patients pa (USA)
- →1m patients with indeterminate outcomes
- BREVAGen re-classifies ~25% of these enabling preventive SERM therapy
- SERMs effective at preventing 69%ER+ BCa & 50% all BCa

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445

BREVAGen™ SNP Panel: Large Discovery, Validation & Prospective Replication Data Sets

BREVAGen™

Discovery & Validation

Stage 1: Genotyped 266,722 SNPs in 440 "High-Risk" Breast Cancer Cases and 400 Controls

↓

Stage 2: Genotyped top 12,711 SNPs in 3990 Invasive Breast Cancer Cases & 3916 Controls

↓

Stage 3: Top 30 SNPs tested in 22,635 Cases (incl. 967 carcinoma in situ) & 20,973 Controls

↓

- 8 SNPs with association $<10^{-7}$
- 5 novel breast cancer risk loci

Prospective Independent Replication

Cohort/ Sponsor	# Pts	SNPs Studied	Association
WHI (USA)	3,328	FGFR2, TNRC9, MAP3K1, LSP1, 8q24, FGF10	BCa risk
Icelandic/ deCODE	13,163	FGFR2	BCa risk
Icelandic/ deCODE	39,161	TNRC9	BCa risk
POSH (UK)	899	FGFR2, TNRC9, MAP3K1, LSP, 8q24	ER+ BCa risk and prognosis
SBCS (Shanghai)	3,027	FGFR2, TNRC9	BCa risk; Asian
Cambridge (UK)	2498	FGFR2	BCa risk; African-American

20+ published studies in over 50,000 women

Easton DF et al.; *Genome-wide association study identifies novel breast cancer susceptibility loci.*; Nature 447:1087-93, 2007.

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445

Oncology Focus

- New technologies driving targeted interventions & extending lives
- **Molecular diagnosis of cancer** is most attractive segment of the Dx industry
- Focused market & efficient sales process
- Strong accelerating growth forecast next 4 years
- Historical APac focus
- **US & EU export market exposure via BREVAGen™**



MDx is the fastest growing segment of the IVD market, led by oncology (34% CAGR)

Source: TSG Partners; Scientia Advisors

** molecular diagnostics*

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445

Financials

Financials (year to June30)

(AUD millions)	2010	2009
Operations revenue	5.80	5.38
Licensing revenue	3.95	6.01
Net income / (loss)	(9.35)	(7.85)
EPS (USD per ADR)	(2.5)	(2.1)
Cash	3.30	7.82



Share Register

- **Shares outstanding** 404.6m
  - Top 20 shareholders 76%
  - Total shareholders (approx.) 2,950
- **Options outstanding (*)** 3.3m
  - (*) Employee options
- **Market cap (Sep13)** AUD13.5m

Trending to profitability and positive cash flows

Dr Paul MacLeman, CEO
paul.macleman@gtglabs.com
+61 419 401 445